[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vulvovaginal-candidiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vulvovaginal-candidiasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,65,100,129,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100497174","early-phase-1-exploring-the-effects-of-an-intravaginal-lactic-acid-gel-on-the-vaginal-microbiome-100497174",false,"NCT05753813","Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome","Inclusion Criteria:\n\n* Age 18-54\n* Female\n* Pre-menopausal\n* Can speak and read in English\n* Displays capacity for informed consent\n* Has had 2 or more documented and\u002For self-reported episodes of symptomatic BV or candida infection in the last year, requiring, over-the-counter or prescription treatment\n\nExclusion Criteria:\n\n* Pregnant or trying to become pregnant\n* Post-menopausal\n* Using NuvaRing device\n* A past medical history of kidney disease, recurrent UTI, and\u002For urinary tract abnormalities\n* Current UTI\n* Using Phexxi as a contraceptive during the collection period of the study",true,"FEMALE","18 Years","54 Years",{"count":20,"type":21},22,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.",[27,28],"Bacterial Vaginosis","Vulvovaginal Candidiasis","RECRUITING","2026-02-18",{"date":32,"type":33},"2026-02-20","ACTUAL",{"date":35,"type":33},"2023-12-15",{"date":37,"type":21},"2026-12-30",{"name":39,"class":40},"Queen's Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100596399","oteseconazole-in-the-treatment-of-adults-with-vulvovaginal-candidiasisvvc-100596399","NCT07044947","Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）","Non-interventional Real-World Study of Oteseconazole in the Treatment of Vulvovaginal Candidiasis","VVC","Inclusion Criteria:\n\n* ≥ 18 years old, female; vulvovaginal signs and symptoms (VSS) score ≥7; Plan to use oteseconazole monotherapy or combination therapy\n\nExclusion Criteria:\n\n* Evidence has shown that the patient whohas been pregnant or lactating; Patients who are participating in or planning to participate in other interventional clinical studies; Other situations determined by the researcher as unsuitable for inclusion in the study",{"count":51,"type":21},3000,"OBSERVATIONAL","Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.",[28],"NOT_YET_RECRUITING","2025-06-23",{"date":58,"type":33},"2025-07-01",{"date":60,"type":21},"2025-08-10",{"date":62,"type":21},"2030-08-10",{"name":64,"class":40},"Beijing Tsinghua Chang Gung Hospital",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100553016","effect-of-a-multi-strain-probiotic-on-recurrent-vulvovaginal-candidiasis-100553016","NCT06480604","Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis","A Pilot Clinical Trial Assessing the Effect of a Multi-strain Probiotic on the Risk of Recurrence and Severity of Symptoms in Females With Recurrent Vulvovaginal Candidiasis","PROVELIA","Inclusion Criteria:\n\nIndividuals meeting ALL of the following criteria will be enrolled for the study:\n\n1. Premenopausal women aged 18-50 years.\n2. Women with a culture-confirmed active episode caused by Candida spp. (albicans or non-albicans) reported within 24-48 hours of evidence of clinical symptoms. (No medications should have been initiated before the sample for culture is collected).\n3. Documented history of recurrence of at least 3 VVC episodes in the last 12 months confirmed by vaginal culture \u002Fclinical diagnosis.\n4. Culture growth of Candida spp. causing VVC.\n5. Random Capillary Blood Glucose of \\\u003C 110mg\u002Fdl.\n6. Willingness to consume the study products for the entire study duration.\n7. Willing to complete all study procedures and comply with study requirements.\n8. Willing to abstain from other supplements or medication.\n9. Ready to give voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria:\n\nIndividuals meeting ANY of the following criteria will be excluded from the study:\n\n1. Post-menopausal and peri-menopausal women.\n2. Pregnant\u002Fbreast-feeding women.\n3. Use of oral or vaginal anti-fungal medication in the last 14 days.\n4. Vaginal culture suggestive of bacterial vaginosis (Nugent's score of 7-10), trichomonas vaginalis or Gardnerella vaginalis.\n5. Participants found positive for Clotrimazole resistance, by vaginal culture \\& sensitivity at screening.\n6. Known allergy to Clotrimazole.\n7. Women not willing to use any form of vaginal medication during the study.\n8. Use of vaginal douching.\n9. Unwillingness to use an appropriate method of contraception.\n10. Diagnosed with compromised immune system, type I and\u002For type II diabetes mellitus, or malignancies.\n11. Use of corticosteroids therapy in the last 30 days.\n12. Use of oral\u002Fsystemic antimicrobial therapy in the last 30 days.\n13. Known allergy to the study products or azoles.\n14. Individuals with a history of frequent infections requiring antibiotic treatments.\n15. Participation in another clinical study(ies) in the last 3 months.\n16. Women who, in the opinion of the Investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the study.\n17. Women with uncontrolled hypertension with systolic blood pressure ≥ 140 mm Hg and\u002For diastolic blood pressure ≥ 90 mm Hg.\n18. Heavy alcohol drinkers defined as follows: For men, consuming more than 4 drinks on any day or more than 14 drinks\u002Fweek. For women, consuming more than 3 drinks on any day or more than 7 drinks\u002Fweek.\n19. Smokers.\n20. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the Investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the individual at undue risk.\n21. Presence of unstable, acutely symptomatic, or life-limiting illness.\n22. Use of any supplements (includes probiotics, post-biotics, herbal supplements, synbiotics, enzyme supplements, vitamins with probiotics) in the last 30 days.","50 Years",{"count":75,"type":21},126,[77],"NA","This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).",[28],[81,82,83,84,85,86,87,88,89],"Microbiome","Probiotic","Recurrent","Vulvovaginal","Candidiasis","RVVC","Vaginal","Chronic","Infection","2024-11-05",{"date":92,"type":33},"2024-11-07",{"date":94,"type":33},"2024-10-15",{"date":96,"type":21},"2025-07",{"name":98,"class":99},"The Archer-Daniels-Midland Company","INDUSTRY",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":15,"sex":16,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":52,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":41},"100509073","safety-of-pregnant-subjects-exposed-to-ibrexafungerp-including-infant-outcomes-100509073","NCT05908682","Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes","A Single-arm Safety Study of Subjects Exposed to Ibrexafungerp Whilst Pregnant, Including Infant Outcomes Up to One Year","Inclusion Criteria:\n\n1. Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp\n2. Subject and\u002For parent\u002Flegal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule\u002Fcompletion of questionnaire and release of medical records\n\n   * Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy.\n\nA self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive.\n\n* A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf.\n\nExclusion Criteria:\n\n1. Females who were not exposed to safety study medications during pregnancy\n2. Refusal to participate in the study\n3. An inability to provide an accurate medical history or give informed consent","0 Years",{"count":109,"type":21},100,"1 Year","This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.",[28,113,114],"Candida Infection","Vaginal Candidiasis",[48,116,117,85,118,119],"Thrush","BREXAFEMME","Vaginal Yeast","Yeast Infection","2024-07-15",{"date":122,"type":33},"2024-07-17",{"date":124,"type":33},"2022-07-28",{"date":126,"type":21},"2029-10-31",{"name":128,"class":99},"Scynexis, Inc.",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100550739","phase-1-efficacy-safety-and-dose-response-of-a-live-biotherapeutic-product-in-women-with-acute-vaginal-infection-100550739","NCT06450990","Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection","Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product (BGY-1601-VT) as a First-line Monotherapy in Women With Acute Vaginal Infection: a Randomized, Double-blind, Placebo-controlled Study","ELINA","Inclusion Criteria:\n\n* Post-menarche woman aged 18 to 50 years old (inclusive),\n* With suspected Bacterial Vaginosis (BV) and\u002For Vulvovaginal Candidiasis (VVC), presenting symptoms of acute vaginal infection\n* No clinically significant and relevant abnormalities of medical history (including mental disorders) or physical examination,\n* Able and willing to participate to the trial by complying with the protocol procedures as evidenced by her dated and signed informed consent form,\n\nExclusion Criteria:\n\n* Other already diagnosed or suspected infectious causes of bacterial vaginal infection (e.g., Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae) within 1 month\n* Current herpes simplex flare-up in the genital area,\n* Vulvar condyloma due to the human papilloma virus;\n* Vulvar dermatoses (e.g.: psoriasis or lichenification);\n* Clinical diagnosis of BV or VVC within 4 months;\n* Treatment with any antibiotic or antifungal therapy (local or systemic) within 2 months, regardless of the indication;\n* Treatment with any local treatment (probiotics, antiseptic, etc.) within 1 month, regardless of the indication;\n* Participant using any intravaginal product (local contraceptive \\[spermicide, hormonal ring\\], moisturizer, tampon, intimate hygiene product, etc.);\n* Participant with a chronic disease or condition or treatment known to impact the immune system, including auto-immune disease, diabetes, cancer, renal failure, etc.\n* Pregnant or breastfeeding patient or intending to become pregnant within 1 month ahead, or having given birth within 3 months;\n* Participant in perimenopause, i.e. aged 45 years or more, with irregular menstrual cycles that could lead to a suspicion of menopause;\n* With a known or suspected food allergy or intolerance or hypersensitivity to any of the trial intervention ingredient;",{"count":138,"type":21},165,[140,141],"PHASE1","PHASE2","The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront microbiological confirmed diagnosis",[27,28],[145,146,147,148,149,150,151,152],"Vaginal infection","Bacterial Vaginosis (BV)","Vulvovaginal Candidiasis (VVC)","Anaerobic bacteria","Prevotella","Gardnerella vaginalis","Candida albicans","Acute Vaginitis","2024-06-10",{"date":155,"type":33},"2024-06-12",{"date":157,"type":21},"2024-07-08",{"date":159,"type":21},"2026-02-26",{"name":161,"class":99},"NEXBIOME THERAPEUTICS",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":185},"100445382","comparative-performance-of-a-vaginal-yeast-test-100445382","NCT05079711","Comparative Performance of a Vaginal Yeast Test","Comparative Performance of the SavvyCheck Vaginal Yeast Test Versus Culture","Inclusion Criteria:\n\nSymptomatic Women Symptomatic women include those women who present with a complaint consistent with symptoms of vaginitis (e.g., increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination). Enrollment will continue at each clinical site until our target number of 216 Reference Method (vaginal Candida yeast culture) positives have been collected. We estimate up to 600 symptomatic women will be enrolled to meet our target.\n\nInclusion Criteria for Symptomatic Women\n\n1. DoD Military Health System beneficiary\n2. Have a healthcare appointment at a recruitment clinic\n3. 18 years of age or older\n4. Must speak and understand English\n5. Able to provide informed consent\n6. Women experiencing vaginal symptoms, including: increased discharge, itching, soreness and irritation, rash on the labia, and genital burning that may worsen during urination\n7. Must determine the test is applicable to her based on her symptoms after she has read the outside device labeling (box label)\n\nAsymptomatic Women Asymptomatic women include those women who do not present with a complaint consistent with vaginitis. Enrollment will continue at each clinical site until our target number of 170 Reference Method (vaginal Candida yeast culture) negatives have been collected. We estimate up to 320 asymptomatic women will be enrolled to meet our target.\n\nInclusion Criteria for Asymptomatic Women:\n\n1. DoD Military Health System beneficiary\n2. Have a healthcare appointment at a recruitment clinic\n3. 18 years of age or older\n4. Must speak and understand English\n5. Able to provide informed consent\n6. Healthy women appearing for routine care without symptoms of vaginal yeast infection\n\nExclusion Criteria:\n\nIf any of the following criteria are met, a potential subject will be excluded from the study:\n\n1. Currently menstruating\n2. History of any clinical therapies and\u002For interventions related to gender confirmation (transgender person)\n3. Use of any vaginal medication, taken by mouth or vaginally, within the last 7 days\n4. Use of any vaginal product within 24 hours, including contraception (cream, gel, or foam), or douching solutions\n\nNOTE: Women who currently have an intrauterine device (IUD) placed are eligible to participate",{"count":170,"type":21},1200,"The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.",[28],[174],"Vaginal candidiasis, Vaginal yeast culture","2024-05-14",{"date":177,"type":33},"2024-05-16",{"date":179,"type":33},"2022-03-18",{"date":181,"type":21},"2026-08-30",{"name":183,"class":184},"Uniformed Services University of the Health Sciences","FED",3]